EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Simultaneous integrated boost intensity-modulated radiotherapy post breast-conserving surgery: clinical efficacy, adverse effects, and cosmetic outcomes in breast cancer patients

Yong-Qiang Bao, Teng-Hua Yu, Wei Huang, Qing-Feng Mao, Gan-Jie Tu, Bin Li, An Yi, Jin-Gao Li, Jun Rao, Huai-Wen Zhang, Chun-Ling Jiang

Breast Cancer · 2024

DOI: 10.1007/s12282-024-01588-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer, 2024. Verfasst von Yong-Qiang Bao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanc…. Hauptthemen laut MEDLINE: Breast Neoplasms, Mastectomy, Segmental, Radiotherapy, Intensity-Modulated. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the Science and Technology Project of Jiangxi Province, Outstanding Youth Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) is an innovative technique delivering a higher dose to the tumor bed while irradiating the entire breast. This study aims to assess the clinical outcomes, adverse effects, and cosmetic results of SIB-IMRT following breast-conserving surgery in breast cancer patients.

Methods

We conducted a retrospective analysis of 308 patients with stage 0–III breast cancer who underwent breast-conserving surgery and SIB-IMRT from January 2016 to December 2020. The prescribed doses included 1.85 Gy/27 fractions to the whole breast and 2.22 Gy/27 fractions or 2.20 Gy/27 fractions to the tumor bed. Primary endpoints included overall survival (OS), local–regional control (LRC), distant metastasis-free survival (DMFS), acute and late toxicities, and cosmetic outcomes.

Results

The median follow-up time was 36 months. The 3-year OS, LRC, and DMFS rates were 100%, 99.6%, and 99.2%, respectively. Five patients (1.8%) experienced local recurrence or distant metastasis, and one patient succumbed to distant metastasis. The most common acute toxicity was grade 1–2 skin reactions (91.6%). The most common late toxicity was grade 0–1 skin and subcutaneous tissue reactions (96.7%). Five patients (1.8%) developed grade 1–2 upper limb lymphedema, and three patients (1.1%) had grade 1 radiation pneumonitis. Among the 262 patients evaluated for cosmetic outcomes at least 2 years post-radiotherapy, 96.9% achieved excellent or good results, while 3.1% had fair or poor outcomes.

Conclusions

SIB-IMRT after breast-conserving surgery in breast cancer patients demonstrated excellent clinical efficacy, mild acute and late toxicities, and satisfactory cosmetic outcomes in our study. SIB-IMRT appears to be a feasible and effective option for breast cancer patients suitable for breast-conserving surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMastectomy, SegmentalRadiotherapy, Intensity-ModulatedHumansFemaleMiddle AgedRetrospective StudiesAgedAdultRadiotherapy, AdjuvantTreatment OutcomeNeoplasm Recurrence, LocalFollow-Up Studies

Stichwörter der Autor:innen

Adverse effectsBreast cancerBreast-conserving surgeryClinical efficacySimultaneous integrated boost intensity-modulated radiotherapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, 330029, Jiangxi, China.
  • Medical Oncology, Nanchang People's Hospital, Nanchang People's Hospital Affiliated of Nanchang Medical College, Nanchang, 330009, Jiangxi, China.
  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
  • Department of Radiation Oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, 330029, Jiangxi, China. raojun1986@126.com.
  • Department of Radiation Oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, 330029, Jiangxi, China. 1761580890@qq.com.
  • Department of Radiation Oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, 330029, Jiangxi, China. jclil2002@163.com.

Förderung

  • the National Natural Science Foundation of China
  • the Science and Technology Project of Jiangxi Province
  • Outstanding Youth Foundation of Jiangsu Province

Zitieren

APA

Bao, Y. Q., Yu, T. H., Huang, W., Mao, Q. F., Tu, G. J., Li, B., Yi, A., Li, J. G., Rao, J., Zhang, H. W., & Jiang, C. L. (2024). Simultaneous integrated boost intensity-modulated radiotherapy post breast-conserving surgery: clinical efficacy, adverse effects, and cosmetic outcomes in breast cancer patients. Breast Cancer. https://doi.org/10.1007/s12282-024-01588-0

Vancouver

Bao YQ, Yu TH, Huang W, Mao QF, Tu GJ, Li B, et al. Simultaneous integrated boost intensity-modulated radiotherapy post breast-conserving surgery: clinical efficacy, adverse effects, and cosmetic outcomes in breast cancer patients. Breast Cancer. 2024. doi:10.1007/s12282-024-01588-0

BibTeX
@article{Bao2024,
  author = {Bao, Yong-Qiang and Yu, Teng-Hua and Huang, Wei and Mao, Qing-Feng and Tu, Gan-Jie and Li, Bin and Yi, An and Li, Jin-Gao and Rao, Jun and Zhang, Huai-Wen and Jiang, Chun-Ling},
  title = {Simultaneous integrated boost intensity-modulated radiotherapy post breast-conserving surgery: clinical efficacy, adverse effects, and cosmetic outcomes in breast cancer patients},
  journal = {Breast Cancer},
  year = {2024},
  doi = {10.1007/s12282-024-01588-0}
}
Kostenlos starten →